Gosset Ownership
Private
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Zevacor Molecular General Information
Prior to its acquisition by Curium in March 2020, Zevacor Molecular was a leading U.S. producer of Strontium‑82 used to manufacture Rubidium‑82 generators for cardiac PET imaging—the most frequently used agent for this purpose in the U.S. The company also developed and distributed a range of radioisotopes for clinical and research use. No therapeutic clinical results as it focused on diagnostic radiopharmaceuticals.
Contact Information
Primary Industry
Medical Imaging
Corporate Office
Noblesville, Indiana
United States
United States
Drug Pipeline
rubidium-82
CommercialKey Partnerships
DMH Worldwide (previous owner prior to Curium acquisition)
Zevacor Molecular Funding
No funding data available
To view Zevacor Molecular's complete valuation and funding history, request access »